Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,025 | 0,034 | 10.05. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.03. | Hemostemix Inc (2): Hemostemix hires Oak Hill for advisory services | 1 | Stockwatch | ||
07.03. | Hemostemix Inc.: Hemostemix Announces Engagement of Oak Hill Asset Management Inc. | 460 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak... ► Artikel lesen | |
06.02. | Hemostemix Inc (2): Hemostemix releases clinical results via Biomedical | 1 | Stockwatch | ||
06.02. | Hemostemix Inc.: Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences | 380 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research... ► Artikel lesen | |
29.12.23 | Hemostemix Inc (2): Hemostemix clarifies Oct. 3 PR on private placement | 3 | Stockwatch | ||
29.12.23 | Hemostemix Inc.: Hemostemix Clarifies its October 3, 2023 News Release | 841 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October... ► Artikel lesen | |
15.12.23 | Hemostemix Inc (2): Hemostemix debentures amended | 2 | Stockwatch | ||
30.10.23 | Hemostemix Inc.: Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease | 537 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh... ► Artikel lesen | |
23.10.23 | Hemostemix Inc.: Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000 | 343 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which... ► Artikel lesen | |
03.10.23 | Hemostemix Inc.: Hemostemix Closed $320,125 Private Placement | 297 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately... ► Artikel lesen | |
27.09.23 | Hemostemix Inc.: Hemostemix Announces Private Placement | 394 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 27, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately... ► Artikel lesen | |
12.09.23 | Hemostemix Inc.: Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces | 447 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has... ► Artikel lesen | |
29.08.23 | Hemostemix Inc.: Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications | 423 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has applied for grant... ► Artikel lesen | |
14.08.23 | Hemostemix Inc.: Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement | 460 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that on August 10, 2023 it received a final cost award from the... ► Artikel lesen | |
08.08.23 | Hemostemix Inc.: Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review | 348 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it submitted for publication its retrospective cardiomyopathy study... ► Artikel lesen | |
28.06.23 | Hemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private Placement | 436 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 28, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price... ► Artikel lesen | |
21.06.23 | Hemostemix Inc.: Hemostemix's Private Placement Use of Proceeds | 477 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to... ► Artikel lesen | |
02.06.23 | Hemostemix Inc.: Hemostemix Announces Unit Private Placement | 432 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 10 Million Units priced at... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PAION | 0,035 | 0,00 % | Paion mit SONDERMELDUNG: Könnte der Kurs JETZT komplett drehen - Anleger müssen SOFORT reagieren! | ||
VALNEVA | 3,346 | 0,00 % | Valneva Aktie: Skepsis trotz Kurserholung | Die Valneva-Aktie hat aktuell einen Kurs von 3,5 € zu verzeichnen und zeigt im Wochenvergleich eine Veränderung um 1,63 % nach oben. Nach einem beinahe turbulenten Abstieg schien die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
EPIGENOMICS | 1,570 | -3,38 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
NOVAVAX | 8,284 | +0,33 % | Novavax Aktie: Aktionäre zu Revolte aufgerufen | Ein bedeutender Anteilseigner eines Biotechnologieunternehmens hat öffentlich Änderungen im Vorstand und Management gefordert, um die sinkende Leistung der Firma umzukehren. Kritik gab es insbesondere... ► Artikel lesen | |
CORE ONE LABS | 0,140 | -1,41 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
DEFENCE THERAPEUTICS | 0,852 | -3,84 % | Bayer auf dem Weg aus der Krise. Stehen auch Defence Therapeutics und BioNTech mit ihren Onkologie-Pipelines vor dem Turnaround? | Nach mehreren Jahren, in denen der Pharma- und Agrarchemiekonzern Bayer von einer Krise in die nächste stolperte, zeichnen sich nun Zeichen einer Erholung am Horizont ab. Während Bayer seinen langen... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 2,005 | +0,96 % | Novo Nordisk, Cardiol Therapeutics, Pfizer - Pharma-Watchlist: Drei Top-Innovatoren | In der sich rasant entwickelnden Welt der Biotechnologie und Pharmaindustrie kann ein einziges Medikament den Unterschied machen. Besonders, wenn diese Medikamente einzigartig sind. Sie entfalten das... ► Artikel lesen | |
ASEP MEDICAL | 0,110 | +9,45 % | Asep Medical bestätigt, dass der Einsatz von KI verbesserte Behandlungen der häufigen Biofilminfektionen und eine schnelle Sepsisdiagnose ermöglicht | VANCOUVER, BC, 13. März 2024 - In seiner jüngsten Präsentation vor der US-amerikanischen Biophysical Society in Philadelphia1 berichtete Dr. Bob Hancock, CEO von Asep Medical Holdings... ► Artikel lesen | |
SPEXIS | 0,063 | -1,10 % | Adhoc: Spexis AG: Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. | Spexis AG / Key word(s): Miscellaneous
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31,... ► Artikel lesen | |
BELLICUM PHARMACEUTICALS | 0,163 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.11.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 20.11.2023.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.11.2023.ISIN NameFR0013318813 PARAGON... ► Artikel lesen | |
TRIVARX | - | - | TRIVARX LTD: Cleansing Notice | ||
ADMA BIOLOGICS | 8,810 | +27,13 % | ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results | ||
QIAGEN | 40,870 | +1,30 % | Qiagen zuletzt sehr stark. Der Montag wird wahnsinnig wichtig! | Grund zum Feiern haben heute alle Qiagen-Aktionäre. Schließlich errechnet sich im Vergleich zur Vorwoche ein Zugewinn von 2,87 Prozent. Das Wertpapier verabschiedete sich an vier der vier Sitzungen... ► Artikel lesen | |
JANUX THERAPEUTICS | 48,920 | -5,81 % | Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
ARCELLX | 49,740 | -5,67 % | Arcellx Provides First Quarter 2024 Financial Results | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen |